GenMedicn Biopharma

What GenMedicn Biopharma does

GenMedicn Biopharma is a privately-held, clinical-stage gene therapy company headquartered in Nanjing, China, with a secondary R&D entity in Tianjin. The company pursues a dual business model: (1) developing its own gene and cell therapy (GCT) drug pipeline targeting rare genetic diseases (with lead asset GMCN-508B for transfusion-dependent β-thalassemia and a parallel α-thalassemia program GMCN-508A), and (2) operating a full-chain GCT professional services platform (delivered through wholly-owned subsidiary Zhongji Dangkang / 中吉当康) that serves biotech companies, clinical genetics experts, and academic researchers. The services span drug discovery, viral vector and plasmid manufacturing, process development, analytical testing, and regulatory registration.

The company's technical core is built around two branded proprietary platforms — AAVecTiQ® (AAV production across adherent 293, suspension 293, and insect cell-baculovirus systems, scalable from hundreds of milliliters to over 100 liters) and LentiQ® (lentiviral production with transduction titers of 1E+8 to 1E+9 TU/mL and HCD residual <20 ng/mL). Supporting technologies include an inducible virus vector production system that eliminates large-scale plasmid/transfection requirements, a gene expression cassette platform for tissue-specific transcriptional regulation, and tissue-targeted AAV capsid and lentiviral envelope modification capabilities. The IP estate comprises 10 granted Chinese patents spanning vector design, VLP development, gene editing, and platform process technologies. Operations are anchored by a 2,600 sqm cGMP-capable pilot workshop in Nanjing Jiangbei New District's Biopharmaceutical Valley.

Revenue mechanics are dominated by B2B service contracts (CDMO-type engagements for plasmids, lentivirus, AAV, and HSC products) priced via customized quotations with multi-year contract cadences; commercial drug revenue is pre-launch. The GTM motion is sales-led and enterprise field-sales oriented, executed via direct outreach, dedicated email channels ([email protected], [email protected]), clinical-expert co-development partnerships, and inbound inquiry forms. The company is founder-controlled by Dr. Dong Wenji (Chairman, postdoc at New York Blood Center) and Dr. Zhang Ye (Co-founder, postdoc at Harvard Medical School), with team members holding PhDs from the Chinese Academy of Medical Sciences and postdocs at Harvard and Cambridge Sanger Institute.

Name

GenMedicn Biopharma

Legal name

中吉智药（南京）生物技术有限公司

Website

https://genmedicn.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

GenMedicn Biopharma is a Nanjing-based clinical-stage gene therapy company developing gene and cell therapy drugs for rare genetic diseases while offering integrated CDMO-type GCT services through proprietary AAVecTiQ® and LentiQ® platforms.

Ownership category

akta.pro rank

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Gene and Cell Therapy (GCT) Professional Services: Full-chain technical services covering: 1) Drug development (early research design and preparation), 2) Manufacturing (clinical trial materials), 3) Process development, 4) Analytical testing, 5) Regulatory registration services. Services provided through subsidiary Zhongji Dangkang.
2. Contract Development and Manufacturing: CDMO-type services for plasmid preparation, lentivirus, AAV, and hematopoietic stem cell products. Services range from research-grade to clinical-grade quality.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

GenMedicn Biopharma is a clinical-stage gene therapy company providing integrated Gene and Cell Therapy (GCT) professional services covering drug development, viral vector and cell product manufacturing (plasmids, lentivirus, AAV, hematopoietic stem cells), process development, analytical testing, and regulatory registration, delivered through its subsidiary Zhongji Dangkang (中吉当康). In parallel, the company advances an in-house drug pipeline anchored by GMCN-508B, a lentiviral gene therapy for transfusion-dependent β-thalassemia that received CDE IND approval in January 2024.

Product overview

GenMedicn Biopharma is a clinical-stage gene therapy company offering an integrated GCT (Gene and Cell Therapy) professional services platform encompassing five core service categories: Drug Development Services, Production Preparation Services (covering plasmid, lentivirus/LV, AAV, and HSC), Analysis Testing Services, Process Development Services, and Regulatory Registration Services. The company operates proprietary technology platforms including AAVecTiQ® for AAV vector production and LentiQ® for lentiviral vector production, supported by inducible virus vector production technology and gene expression cassette technologies. The drug pipeline includes GMCN-508B for β-thalassemia (IND approved in January 2024) and GMCN-508A for α-thalassemia (preclinical stage). Services are delivered through a 2600 sqm GMP pilot workshop in Nanjing and molecular biology facilities in Tianjin.

Differentiator

Problem solved

Functional benefit

Brands

• AAVecTiQ®: AAV (Adeno-Associated Virus) vector production platform enabling scalable virus vector manufacturing from hundreds of milliliters to hundreds of liters
• LentiQ®

Products and services

• GCT Professional Services (Gene and Cell Therapy Professional Services / GCT专业服务) Comprehensive professional technical services covering the full gene and cell therapy drug development lifecycle: drug discovery, manufacturing, process development, bioassay services, and regulatory registration. Delivered to biotech companies, clinical genetics experts, and rare disease researchers.
• AAVecTiQ® AAV Production Platform

Quantifiable outcome

• Transduction efficiency of 91.44% positive rate for human CD34+ hematopoietic stem cells using LentiQ® high-purity EGFP lentivirus
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Clinical Genetics Experts and Rare Disease ResearcherscoreStrategic or Co-development PartnerCollaborative partnerships with clinical experts who have clear understanding of pathogenic genes and disease mechanisms in genetic diseases. Jointly developing gene therapy drugs with clinical experts to efficiently advance gene therapy development from research to clinical application.
• Xuzhou Medical UniversityminorStrategic or Co-development PartnerDr. Chen Bo from GenMedicn appointed as 2025 University-level and Provincial-level Industry Professor at Xuzhou Medical University, indicating academic collaboration and talent development partnership.

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• BRL Medicine (纽福斯生物): Chinese clinical-stage gene therapy company developing AAV-based ophthalmology and rare disease therapies. Same business model combining in-house drug pipeline with vector platform capabilities; comparable gene therapy execution risk profile.
• Genscript ProBio: CDMO subsidiary of Genscript providing plasmid, viral vector (AAV/lentivirus), and cell therapy manufacturing services. Most direct comparable to GenMedicn's GCT professional services offering for plasmid prep, LV, AAV, and HSC products.
• Cibus Bio / Vigene Biosciences: Viral vector CDMO specializing in AAV and lentiviral production for gene therapy developers. Comparable CDMO service offering focused on the same vector types (AAV/LV) that GenMedicn provides through its Zhongji Dangkang subsidiary.
• Belief Bio (信念医药): Chinese gene therapy biotech developing AAV-based therapies for rare diseases including hemophilia. Comparable in gene therapy focus and rare disease pipeline, and overlaps in AAV manufacturing capabilities with GenMedicn's platform.
• Refreshgene (瑞吉生物): Chinese gene therapy biotech developing lentiviral and AAV-based therapies for genetic diseases including hemophilia. Direct overlap with GenMedicn's lentiviral hematologic disease focus (β-thalassemia).

Regional players

• Yposkesi (Cell & Gene Therapy CDMO): Europe-based viral vector CDMO offering AAV and lentiviral manufacturing. Comparable viral vector CDMO business but primarily serves European customers; benchmark for GenMedicn's international expansion potential.

Broad incumbents

• bluebird bio: Pioneer in lentiviral-based gene therapies with approved products for β-thalassemia (Zynteglo) and sickle cell disease. The most established global reference point for GenMedicn's GMCN-508B lentiviral β-thalassemia program.
• WuXi Advanced Therapies (WuXi AppTec): Global CDMO with a large gene and cell therapy service arm offering viral vector and cell product manufacturing at scale. Direct competitor to GenMedicn's CDMO side; broader portfolio and deeper global reach make it a broad incumbent in the same viral vector manufacturing space.

Emerging players

• Beam Therapeutics: Clinical-stage gene therapy / gene editing biotech developing precision medicines for genetic diseases. Comparable in using lentiviral delivery to hematopoietic cells and pursuing rare disease gene therapy applications.
• Shanghai Juncell Therapeutics (上海君赛生物): Chinese cell and gene therapy company focused on novel cell therapy platforms. Comparable emerging clinical-stage gene/cell therapy player in the Chinese market with similar gene therapy pipeline ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenMedicn Biopharma